Insilico Medicine Forms Longevity Board to Guide AI Aging Research

Insilico Medicine has announced the creation of the industry's first Longevity Board to advance research in aging and drug discovery in a press release. The board will guide projects that use artificial intelligence to identify and validate therapeutic targets linked to aging and disease.

The Longevity Board will be chaired by Andrew Adams, Group Vice President of Molecular Discovery at Eli Lilly and Company. Other members include Nobel laureate Michael Levitt, Denitsa Milanova of Medici Therapeutics, and Insilico co-CEOs Alex Zhavoronkov and Feng Ren. The board will oversee work in biomarkers of aging, dual-purpose therapeutic targets, and clinical validation using foundation models.

According to Insilico, the initiative aims to connect pharmaceutical development with longevity science by integrating insights from large-scale R&D operations into its generative AI platform. The company stated that this approach will help accelerate the transition of experimental longevity compounds into viable medicines for mainstream healthcare.

Insilico Medicine, listed on the Hong Kong Stock Exchange under code 03696.HK, applies AI and automation to drug discovery in areas such as fibrosis, oncology, immunology, pain, and metabolic disorders.